Bionet

Bionet FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Bionet (1784.TWO) as of Nov 2, 2026 is 30.83 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 87.22 % — a change of -64.65% (lower).

FCF Conversion

30.83 %

YoY

-64.65%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Bionet is 2025 30.83 % . FCF Conversion Rate (FCF/EBITDA) of Bionet was 2024 87.22 % . It decreases by -64.65% lower compared to the previous year.

The Bionet FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-122.15 TWD
Jan 1, 2019
-131.31 TWD
Jan 1, 2020
279.61 TWD
Jan 1, 2021
-10.47 TWD
Jan 1, 2022
162.61 TWD
Jan 1, 2023
161.75 TWD
Jan 1, 2024
87.22 TWD
Jan 1, 2025
30.83 TWD
The Bionet FCF Conversion history
YEARFCF ConversionYoY
30.83 %-64.65%
87.22 %-46.08%
161.75 %-0.53%
162.61 %-1,653.38%
-10.47 %-103.74%
279.61 %-312.94%
-131.31 %+7.50%
-122.15 %-121.96%
556.15 %+49.71%
371.48 %+159.14%
143.35 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bionet Stock analysis

What does Bionet do? Bionet Corp. generates revenue through cell therapy, regenerative medicine, and medical big data services. Its main products include umbilical cord blood stem cells, mesenchymal stem cells, and adult peripheral blood stem cells, which are sold to domestic healthcare providers. The company also offers precision medical applications, prenatal testing, and genetic testing services to domestic clients. The firm primarily serves the domestic market within Taipei City, Taipei, focusing on medical and healthcare segments. Bionet Corp. targets healthcare institutions and medical facilities in Taiwan as its primary customers. The company's product portfolio includes stem cell therapies and genetic testing services, which are distributed through its domestic operations. Revenue streams are derived from both the sale of biological products and the provision of specialized medical services within the local market. The business model relies on domestic sales of stem cell-based therapies and genetic testing services. Products such as umbilical cord blood stem cells and mesenchymal stem cells are key revenue drivers, alongside precision medical applications and prenatal testing. All operations are conducted within Taiwan, with no mention of international markets or external partnerships. Bionet is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bionet stock

FCF Conversion Rate (FCF/EBITDA) of Bionet is 30.83 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Bionet changed from 87.22 % to 30.83 %, representing a -64.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Bionet since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Bionet with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Bionet

All Key Metrics — Bionet